TOPIC
 / company

Insilico Medicine

(英矽智能)

Related Topics:
Insilico Medicine
英矽智能
Insilico, based in Boston and Hong Kong, uses end-to-end generative artificial intelligence (AI) to identify novel targets and disease hypotheses and generative innovative drug candidates. Its Pharma.AI platform operates across biology, chemistry and clinical medicine to identify drug candidates.
Hong Kong stock market

Hong Kong stocks edge higher on last full trading day of year

Hang Seng Index edges higher as Chinese yuan surpasses 7 against US dollar for first time since May 2023.

China vital to Insilico’s plan to build biotech’s AI ‘Einstein’ for new drugs

Holiday rush: Hong Kong IPO market sparkles with busiest December in years

From biotech to AI, December’s listings – including at least 15 down the stretch – crown the city’s revival in equity fundraising.

China’s drug innovators bank on AI to hasten discovery to commercial success

A deal between Shenzhen-based XTalPi and US firm DoveTree shows Chinese biotech AI capabilities are gaining recognition.

videocam
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement